2024年7月11日 · Paxlovid is available to anyone ages 12 and up, depending on their risk for severe illness from COVID. The Food and Drug Administration (FDA) gave the drug full approval in May 2023 for adults with mild-to-moderate COVID at high risk for severe disease, hospitalization, and death.

2025年1月2日 · Pemgarda (pemivibart) is the newest medication for COVID. But it’s not designed to treat COVID. Pemgarda helps prevent COVID in certain adults and kids ages 12 years and older. It was authorized for emergency use in March 2024.

Today, the U.S. Food and Drug Administration approved the oral antiviral Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate...

2025年3月10日 · FDA has authorized or approved several antiviral medications used to treat mild to moderate COVID-19 in people who are more likely to get very sick. Antiviral medications target specific parts of the virus to stop it from multiplying in the body once someone is infected, helping to prevent severe illness and death.

2025年3月12日 · The SCORPIO-PEP trial found the drug ensitrelvir, already approved in Japan to treat people with mild to moderate COVID-19, may protect against the illness. In the study, uninfected people who began taking the antiviral within 72 hours of a household member developing symptoms were significantly less likely to contract COVID-19 than people who ...

Antiviral drugs are medicines (pills, liquid, an inhaled powder, or an intravenous solution) that fight against viruses in your body. Immune modulators are medicines that help activate,...

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the...

2025年3月14日 · The results mean that the drug lowered the risk of getting COVID-19 by 67%. The idea of using an antiviral treatment to protect people at high risk of infection isn’t new.

2024年9月3日 · BioVie Inc announced today that the FDA has authorized their Investigational New Drug application to evaluate bezisterim (NE3107) for the treatment of patients with neurological symptoms associated with long COVID, according to …

2024年4月15日 · In this Review, we summarize the major drug discovery approaches, preclinical antiviral evaluation models, representative virus-targeting and host-targeting therapeutic options, and key...